Valuations of Early-Stage Companies and Disruptive Technologies

lt;p>Tiran Rothman has over a decade of experience in financial consultancy and academic and applied research in behavioral finance and economics. As a vice president of Frost & Sullivan, he leads the largest private financial valuation program for high-tech companies and the Tel Aviv Stock Exchange Equity Research Program, involving pharmaceutical, biotechnology, medical device, ICT, renewable energy, autonomous vehicle and cybersecurity companies. He previously served as the Chief Economist of AMPAL (NASDAQ: AMPL). Tiran is also an Assistant Professor at the WIZO Academic Center Haifa in Israel. He holds a PhD in Behavioral Economics from the University of Haifa, an MBA in Finance from IDC Herzliya and was a visiting fellow at New York University's Stern Business School. He has published widely in the field of behavioral finance and has been the recipient of numerous research grants and scholarships.

Part I. A Short Overview of Valuations.- Chapter 1. Introduction.- Chapter 2. Understanding Financial Valuations and Basic Traditional Techniques.- Part II. Overcoming Valuation Hurdles: How to Conduct Valuations Under Unique Circumstances.- Chapter 3. Understanding the Basic Elements of Stockholder Statements and their Use in Valuations.- Chapter 4. Valuation Methods: The First Chicago Venture Method and the Use of Real Options.- Part III. Behavioral Factors: How Psychology Affects Bias in Valuations.- Chapter 5. Introduction to Behavioral Finance.- Chapter 6. An Overview of Investor Behavior in Financial Markets and Psychological Influences on Valuations.- Chapter 7. How to Overcome Investor Behavior and Psychological Influences in Valuations: How to Evaluate a Dream?.- Part IV. An Introduction to Valuations in R&D-Intensive Industries.- Chapter 8. The Pharmaceutical Sector.- Chapter 9. Life Sciences: Disrupting Biologic Drugs Manufacturing.- Chapter 10. An Overview of the Cybersecurity and the Renewable Energy Sectors.- Part V. Actual Valuations.- Chapter 11. Company A: Pharmaceutical / New Compounds.- Chapter 12. Company B: Pharmaceutical / Biologies.- Chapter 13. Company C: Cybersecurity.- Chapter 14. Company D: Renewable Energy.- Chapter 15. Conclusion.